GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
Clinical trial NCT05686551 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05686551
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-03
- Primary completion
- 2026-05-14
- Enrollment
- 301
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.